Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children
about
Advances and challenges in malaria vaccine developmentEuropean Vaccine Initiative: lessons from developing malaria vaccinesA review of malaria vaccine clinical projects based on the WHO rainbow tableMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaLimited variation in vaccine candidate Plasmodium falciparum Merozoite Surface Protein-6 over multiple transmission seasonsEngaging diverse communities participating in clinical trials: case examples from across Africa.Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoitesBlood stage vaccines for Plasmodium falciparum: current status and the way forward.Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.Malaria immunoepidemiology in low transmission: correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein 3Rhipicephalus microplus and Ixodes ovatus cystatins in tick blood digestion and evasion of host immune response.Allelic Diversity and Geographical Distribution of the Gene Encoding Plasmodium falciparum Merozoite Surface Protein-3 in Thailand.Health providers' perceptions of clinical trials: lessons from Ghana, Kenya and Burkina Faso.Expression and Evaluation of Recombinant Plasmodium knowlesi Merozoite Surface Protein-3 (MSP-3) for Detection of Human Malaria.Recent advances in recombinant protein-based malaria vaccines.Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study.Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.Genetic diversity of the merozoite surface protein-3 gene in Plasmodium falciparum populations in Thailand.Blood-stage malaria vaccines - recent progress and future challenges.Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell ResponsesAntibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso.FcγRIIa polymorphism and anti-malaria-specific IgG and IgG subclass responses in populations differing in susceptibility to malaria in Burkina Faso.
P2860
Q21032463-C6766846-4E83-44EA-A7A1-87C5D0AD7281Q21032652-D0710306-2AFB-44CA-967C-9B81ADB4A889Q21034112-476D22EE-4BC6-4874-B427-EEF9524E0789Q26772878-44ADC073-73D0-45BC-AEFA-67776DDD7317Q33898582-8C0894BE-9F0C-4CB1-93E5-184F35EBF249Q34010897-8143FD27-7692-450F-B3B6-1A60BCCB28C3Q34540211-A4B062C6-92D5-424F-80E4-AEA76429299EQ34663978-BA91D437-5304-4867-ADE2-FFFC96F25949Q34749432-7523DA0B-A545-491E-BC57-A4D35CA28B4EQ34931887-25892259-8C1D-4E37-B6F5-570EE3F2A017Q35122741-A80B4292-CB40-4B6E-8F8C-765436044456Q35559584-95361C6E-4D4B-4C86-B9EC-FFA1FF03D6E1Q35560610-23A2F83A-B93D-4311-9471-8DEB864D650BQ36071148-52B9B205-E898-466A-9E78-FDF661FF004BQ36394182-D9DD6242-5248-484D-867A-1AF4B2699F30Q37265801-473DFD81-EB53-4756-AF8F-5FE2AB3D960DQ37310848-616ACC57-EC52-4B36-8214-B2A3B53AD82EQ37356579-7B99603E-925C-4EDE-9445-35A46FBA6742Q37761208-02611C3D-D5B7-4058-8B89-FE4D54AC0CC6Q37791308-EF7F58C1-D88F-47DC-831B-E74B6408D665Q38582086-924FDC85-E3AE-47E9-8ABA-3B4B14E042B8Q40059998-D1716148-B665-48D0-BD46-BB5FC0B953E9Q43929748-472B9ED5-C6CA-4A66-AD8C-B38F7B5A5A2A
P2860
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and immunogenicity of t ...... months-old Burkinabe children
@ast
Safety and immunogenicity of t ...... months-old Burkinabe children
@en
Safety and immunogenicity of t ...... months-old Burkinabe children.
@nl
type
label
Safety and immunogenicity of t ...... months-old Burkinabe children
@ast
Safety and immunogenicity of t ...... months-old Burkinabe children
@en
Safety and immunogenicity of t ...... months-old Burkinabe children.
@nl
prefLabel
Safety and immunogenicity of t ...... months-old Burkinabe children
@ast
Safety and immunogenicity of t ...... months-old Burkinabe children
@en
Safety and immunogenicity of t ...... months-old Burkinabe children.
@nl
P2093
P2860
P50
P1433
P1476
Safety and immunogenicity of t ...... months-old Burkinabe children
@en
P2093
Abdoulaye Traoré
Adama Gansané
Adrian J F Luty
Alfred B Tiono
Alphonse Ouédraogo
Amadou T Konaté
Amidou Diarra
Edith C Bougouma
Espérance Ouédraogo
Issa Nébié
P2860
P356
10.1371/JOURNAL.PONE.0007549
P407
P577
2009-10-26T00:00:00Z